Bayer CEO: China sales to double by 2015; Amgen asks FDA to OK Xgeva cancer use;

@FiercePharma: Good news, bad news from diabetes gathering. Report | Follow @FiercePharma

> Bayer plans to double its sales in China to €6 billion ($8.59 billion) by 2015, local media reported, citing the firm's chief executive. Article

> As promised, Amgen has applied for FDA approval to expand the use of its bone treatment Xgeva to prevent or delay the spread of advanced prostate cancer. Release | Report

> Altaire Pharmaceuticals recalled about 898,000 bottles of Rugby Children's Pain & Fever Concentrated Drops, a medicine containing acetaminophen, for a lack of required child-resistant packaging. Story

> Watson Pharmaceuticals said the FDA has accepted its marketing application for Prochieve, a progesterone gel that is designed to reduce the risk of premature birth. News

> Watson Pharmaceuticals also announced that it has asked FDA to approve its generic version of GlaxoSmithKline's prostate drug Avodart and Novartis' eye drug Pataday. Report

Biotech News

  @FierceBiotech: Study: India's R&D efforts should turn to drug collaborations. Article | Follow @FierceBiotech

@JohnCFierce: Turn out the lights, the party is over at San Diego-based Transdel. News | Follow @JohnCFierce

> China to spend $308B, gain 1M new jobs in 5-year biotech plan. News

> Gilead inks one combo HIV drug pact as it explores new ties with J&J. Item

> Live from BIO 2011: Otologic looks to cure hearing loss. Story

> Nimbus will use $24M round to create new biotech model. Report

Manufacturing News

> For Ranbaxy, FDA visit is much more than a plant inspection. Story

> Merck, Six Sigma and 360-degree problem solving. News

> Endo illustrates two types of labeling recalls. Article

> KV trains regulatory, GMP firepower on comeback. Item

> Manufacturers mostly mum on drug shortages. Item

> REMS costs calculated in study. Report

Biotech Research News

> Scientists crack histamine code that could lead to better allergy relief. Report

> Following up on great expectations for stem cell clinical trials. Article

> Diabetes more than doubled since '80; promising research highlighted. News

> Academic/pharma matches made in biotech heaven...mostly. Story

> Some breast cancers could be treated with prostate cancer drugs. Item

And Finally... Today in a ceremony in Rome, the United Nations is officially declaring that for only the second time in history, a disease has been wiped off the face of the earth. Item

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.